Regulatory Pros Spend More Time on Strategy
RAPS survey finds most regulatory professional have multiregional or worldwide responsibilities and are spending more time on strategic activities.
The Regulatory Affairs Professionals Society (RAPS) released its biennial survey, the 2016 Scope of Practice & Compensation Report for the Regulatory Profession, featuring results from 3,358 regulatory professionals in 56 countries.
Among the most significant findings, regulatory professionals are spending more of their time on strategic activities and less time on tasks related to research and development, clinical testing, product registration and other preapproval activities. Overall, compensation has increased, but more for those at mid-level positions, than those at senior levels.
Most regulatory professionals have multiregional or worldwide responsibilities, and work with multiple types of healthcare products. More than 88% of regulatory professionals began working in another field before transitioning into regulatory, and most have significant prior professional experience, usually in a related field., and more than 20% have a doctorate.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
